Browse recent medication, recall, and health-related stories.
Page 50 of 51
MONTVALE, N.J.,, Sept. 22, 2026 /PRNewswire/ -- Red Oak Wellness, a new licensed and accredited outpatient mental health treatment provider, is expected to open its doors in Montvale, NJ, in October 2026. The center will offer a full continuum of outpatient care for adults facing...
MONTVALE, N.J.,, Sept. 22, 2026 /PRNewswire/ -- Red Oak Wellness, a new licensed and accredited outpatient mental health treatment provider, is expected to open its doors in Montvale, NJ, in October 2026. The center will offer a full continuum of outpatient care for adults facing...
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and inflammatory diseases, announced today that it will host an in-person investor event with a live webcast on Tuesday, October 20, 2026, beginning at 8:30 AM ET, in New York City.
SNS Insider projects the Global Drug-Coated Balloon Catheters Market is projected to reach USD 2.78 billion by 2035, growing at a 8.45% CAGR, while the U.S. market is projected to reach USD 1,022.10 million, advancing at 8.30% CAGR, as next-generation drug coatings and minimally invasive vascular interventions expand catheterization adoption. SNS Insider projects the Global Drug-Coated Balloon Catheters Market is projected to reach USD 2.78 billion by 2035, growing at a 8.45% CAGR, while the U.S. market is projected to reach USD 1,022.10 million, advancing at 8.30% CAGR, as next-generation drug coatings and minimally invasive vascular interventions expand catheterization adoption.
Dear Doctors: I’m a 74-year-old woman in good health. During any medical visit, if I have any issues, I’m prescribed an additional medication. I don’t feel like the list of medications is reviewed, it just gets added to. What advice can you offer to narrow down all of it?
President John Dramani Mahama has said Ghana’s efforts to reset its health sector must go beyond the construction of hospitals and medical facilities to developing the country’s capacity to manufacture essential medicines locally.
The FDA gave the green light to a first and only sirolimus drug-eluting balloon designed by Cordis to treat coronary in-stent restenosis.
Agreement: I Agree Body: Dear Editor, Blanc et al’s study provides valuable insight into how people pursuing assisted suicide understand and articulate their decision and its motivations. Their findings demonstrate that these choices are multifactorial and that influencing factors range beyond physical symptoms and immediate suffering. Additionally, I feel that the social and biographical context in which these preferences develop merits further exploration. For example, several participants reported developing an interest in assisted suicide before becoming seriously unwell, with some joining right-to-die associations ‘long before’ this – something which is presented as both an expression of their values and as a safeguard for the future. Other recent studies found that between 61-63% of Swiss people would consider asking for assisted suicide in certain circumstances [1, 2]. Thus, the prevalence (up to 5% [3]), social acceptability and legality of assisted suicide in Switzerland is an important backdrop to these participant’s perception of autonomy and what constitutes a ‘good death’, ideas which are perhaps then reinforced by the development of illness. Multiple participants also described trauma related to witnessing loved ones’ end-of-life suffering. Such prior experiences may inform expectations around their own illness and potential deterioration and shape a determination to avoid similar circumstances. A 2022 study showed that 88% of individuals in the U.S. with a family history of dementia supported legalising assisted suicide – this compared to around 66% of the general population [4] – potentially illustrating a similar association. Conversely, other participants in the study spoke of positive experiences of assisted suicide in those close to them, which may also have influenced their subsequent opinion of assisted suicide as a familiar, reassuring model of dying. There is scope for future qualitative and longitudinal research to further explore these societal and biographical contexts, building on the insights provided by Blanc et al. in this study. References: [1] Vilpert S, Bolliger E, Borrat-Besson C, Borasio GD, Maurer J. Social, cultural and experiential patterning of attitudes and behaviour towards assisted suicide in Switzerland: evidence from a national population-based study. Swiss Med Wkly. 2020;150:w20275. doi:10.4414/smw.2020.20275. [2] Blanc S, Meier C, Gamondi C, Maurer J, Jox RJ. Preparing for the end-of-life: public attitudes towards advance directives and assisted suicide in Switzerland. BMC Palliat Care. 2025;24:118. doi:10.1186/s12904-025-01758-7. [3] Blanc S, Heistrüvers L, Savinelli S, Bernard M, Borasio GD, Jox RJ, et al. How patients explain and make sense of their decision for assisted suicide in Switzerland (the Exit Project): qualitative exploratory study. BMJ. 2026;394:e100610. doi:10.1136/bmj-2026-100610. [4] Yi R. Most Americans favor legal euthanasia. Gallup [Internet]. 2024 Aug 8 [cited 2026 Sep 21]. No competing Interests: Yes The following competing Interests: Electronic Publication Date: Tuesday, September 22, 2026 - 07:29 AI use: No, I have not used AI Highwire Comment Subject: How patients explain and make sense of their decision for assisted suicide in Switzerland (the Exit Project): qualitative exploratory study Workflow State: Released Full Title: The social and biographical context of assisted-suicide requests Highwire Comment Response to: How patients explain and make sense of their decision for assisted suicide in Switzerland (the Exit Project): qualitative exploratory study Check this box if you would like your letter to appear anonymously:: Last Name: Munro First name and middle initial: Isabelle Email: isabelle.munro1@nhs.net Address: Westminster Bridge Road, SE1 7EH Occupation: Resident Doctor Affiliation: Guy's and St Thomas' NHS Trust BMJ: Additional Article Info: Rapid response
CDSCO identified 220 NSQ drug samples in August 2026, including 29 from central labs and 191 from state labs, and a spurious drug in Delhi.
11-year-old Iraqi girl battles Wilson's disease, gets lifesaving transplant in India
A phase 2 trial of Roche’s dual GLP-1/GIP receptor agonist has hit its primary endpoints, painting the drug candidate as a potential treatment for people with Type 2 diabetes and overweight or obesity.
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and inflammatory diseases, announced today that it will host an in-person investor event with a live webcast on Tuesday, October 20, 2026, beginning at 8:30 AM ET, in New York City.
SNS Insider projects the Global Drug-Coated Balloon Catheters Market is projected to reach USD 2.78 billion by 2035, growing at a 8.45% CAGR, while the U.S. market is projected to reach USD 1,022.10 million, advancing at 8.30% CAGR, as next-generation drug coatings and minimally invasive vascular interventions expand catheterization adoption. SNS Insider projects the Global Drug-Coated Balloon Catheters Market is projected to reach USD 2.78 billion by 2035, growing at a 8.45% CAGR, while the U.S. market is projected to reach USD 1,022.10 million, advancing at 8.30% CAGR, as next-generation drug coatings and minimally invasive vascular interventions expand catheterization adoption.
Dear Doctors: I’m a 74-year-old woman in good health. During any medical visit, if I have any issues, I’m prescribed an additional medication. I don’t feel like the list of medications is reviewed, it just gets added to. What advice can you offer to narrow down all of it?
President John Dramani Mahama has said Ghana’s efforts to reset its health sector must go beyond the construction of hospitals and medical facilities to developing the country’s capacity to manufacture essential medicines locally.
Agreement: I Agree Body: Dear Editor, Blanc et al’s study provides valuable insight into how people pursuing assisted suicide understand and articulate their decision and its motivations. Their findings demonstrate that these choices are multifactorial and that influencing factors range beyond physical symptoms and immediate suffering. Additionally, I feel that the social and biographical context in which these preferences develop merits further exploration. For example, several participants reported developing an interest in assisted suicide before becoming seriously unwell, with some joining right-to-die associations ‘long before’ this – something which is presented as both an expression of their values and as a safeguard for the future. Other recent studies found that between 61-63% of Swiss people would consider asking for assisted suicide in certain circumstances [1, 2]. Thus, the prevalence (up to 5% [3]), social acceptability and legality of assisted suicide in Switzerland is an important backdrop to these participant’s perception of autonomy and what constitutes a ‘good death’, ideas which are perhaps then reinforced by the development of illness. Multiple participants also described trauma related to witnessing loved ones’ end-of-life suffering. Such prior experiences may inform expectations around their own illness and potential deterioration and shape a determination to avoid similar circumstances. A 2022 study showed that 88% of individuals in the U.S. with a family history of dementia supported legalising assisted suicide – this compared to around 66% of the general population [4] – potentially illustrating a similar association. Conversely, other participants in the study spoke of positive experiences of assisted suicide in those close to them, which may also have influenced their subsequent opinion of assisted suicide as a familiar, reassuring model of dying. There is scope for future qualitative and longitudinal research to further explore these societal and biographical contexts, building on the insights provided by Blanc et al. in this study. References: [1] Vilpert S, Bolliger E, Borrat-Besson C, Borasio GD, Maurer J. Social, cultural and experiential patterning of attitudes and behaviour towards assisted suicide in Switzerland: evidence from a national population-based study. Swiss Med Wkly. 2020;150:w20275. doi:10.4414/smw.2020.20275. [2] Blanc S, Meier C, Gamondi C, Maurer J, Jox RJ. Preparing for the end-of-life: public attitudes towards advance directives and assisted suicide in Switzerland. BMC Palliat Care. 2025;24:118. doi:10.1186/s12904-025-01758-7. [3] Blanc S, Heistrüvers L, Savinelli S, Bernard M, Borasio GD, Jox RJ, et al. How patients explain and make sense of their decision for assisted suicide in Switzerland (the Exit Project): qualitative exploratory study. BMJ. 2026;394:e100610. doi:10.1136/bmj-2026-100610. [4] Yi R. Most Americans favor legal euthanasia. Gallup [Internet]. 2024 Aug 8 [cited 2026 Sep 21]. No competing Interests: Yes The following competing Interests: Electronic Publication Date: Tuesday, September 22, 2026 - 07:29 AI use: No, I have not used AI Highwire Comment Subject: How patients explain and make sense of their decision for assisted suicide in Switzerland (the Exit Project): qualitative exploratory study Workflow State: Released Full Title: The social and biographical context of assisted-suicide requests Highwire Comment Response to: How patients explain and make sense of their decision for assisted suicide in Switzerland (the Exit Project): qualitative exploratory study Check this box if you would like your letter to appear anonymously:: Last Name: Munro First name and middle initial: Isabelle Email: isabelle.munro1@nhs.net Address: Westminster Bridge Road, SE1 7EH Occupation: Resident Doctor Affiliation: Guy's and St Thomas' NHS Trust BMJ: Additional Article Info: Rapid response
A phase 2 trial of Roche’s dual GLP-1/GIP receptor agonist has hit its primary endpoints, painting the drug candidate as a potential treatment for people with Type 2 diabetes and overweight or obesity.